NCT01329549 - Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions

Ovarian Neoplasms

Interventions

DRUG

BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min

BIBF 1120 twice daily along with standard therapy of PLD + CBDCA

DRUG

BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min

BIBF 1120 twice daily along with standard therapy of PLD + CBDCA

DRUG

BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min

BIBF 1120 twice daily along with standard therapy of PLD + CBDCA

Trial Locations (3)

1199.117.003 Boehringer Ingelheim Investigational Site, Akashi, Hyogo

1199.117.002 Boehringer Ingelheim Investigational Site, Chuo-ku,Tokyo

1199.117.001 Boehringer Ingelheim Investigational Site, Hidaka, Saitama